Unknown PHASE4 INTERVENTIONAL 2-arm NCT02493179

Efficacy Evaluation of the (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery

Efficacy Evaluation of the Dose Regimen of Serratiopeptidase (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery

Sponsor: Hayat Pharmaceutical Co. PLC

Conditions Inflammation Swelling Trismus

Interventions Placebo Serodase 5 mg

Updated 7 times since 2017 Last updated: Jul 6, 2015 Started: Jun 30, 2015 Primary completion: Jan 31, 2016 Completion: Feb 29, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02493179, this PHASE4 trial focuses on Inflammation and Swelling and remains ongoing. Sponsored by Hayat Pharmaceutical Co. PLC, it has been updated 7 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Aug 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Feb 2017 — Aug 2017 [monthly]

Not Yet Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting PHASE4

First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hayat Pharmaceutical Co. PLC

Data source: Hayat Pharmaceutical Co. PLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.